View Author
patient diabetes mellitus hepatitis diabetes treatment mellitu study resistance hepatitis b response hepatology hepatitis c follow-up virological analysis virological response therapy na-na baseline brosi hepatocellular carcinoma virus na-na ıve patients liver cirrhosis level factor etv monotherapy week 48 ishak score hbv dna fi brosis monotherapy effect hbeag interquartile range virological breakthrough platelet count ef ficacy month entecavir treatment adaptation gastroenterology serum lam resistance bristol-myers squibb presence development center hepatocellular population baseline hbv dna table range hepatitis c patients alcohol abuse carcinoma department liver disease insulin albumin alcohol ratio week 48. genotypic cohort na-experienced genotype platelet model regression bilirubin na-experienced patients hepatitis c virus genotypic resistance count diabetes mellitus increases hbeag status insulin resistance
3 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
(Article)
Zoutendijk, R. Reijnders, J.G.P. Bömmel, F. van Pradat, P. Oo, Y. Luetgehetmann, M. Berg, T. Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. Brown, A. Zoulim, F. Mutimer, D. Deterding, K. Petersen, J. Hofmann, W.P. Buti, M. Santantonio, T. |
2011-08-01
|
|
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
(Article)
Veldt, B.J. Chen, W. Schalm, S.W. Janssen, H.L.A. Heathcote, E.J. Wedemeyer, H. Reichen, J. Hofmann, W.P. Knegt, R.J. de Zeuzem, S. Manns, M.P. Hansen, B.E. |
2008-06-01
|
